Landscape Capital Management L.L.C. Invests $699,000 in Biohaven Ltd. (NYSE:BHVN)

Landscape Capital Management L.L.C. bought a new stake in Biohaven Ltd. (NYSE:BHVN) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 18,710 shares of the company’s stock, valued at approximately $699,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bryce Point Capital LLC acquired a new position in shares of Biohaven in the fourth quarter valued at about $1,195,000. Geode Capital Management LLC boosted its position in Biohaven by 11.1% in the fourth quarter. Geode Capital Management LLC now owns 1,905,366 shares of the company’s stock valued at $71,182,000 after buying an additional 190,754 shares during the last quarter. Alliancebernstein L.P. increased its holdings in Biohaven by 6.6% in the 4th quarter. Alliancebernstein L.P. now owns 96,236 shares of the company’s stock worth $3,594,000 after buying an additional 5,951 shares during the period. Wellington Management Group LLP increased its holdings in Biohaven by 160.7% in the 4th quarter. Wellington Management Group LLP now owns 634,055 shares of the company’s stock worth $23,682,000 after buying an additional 390,888 shares during the period. Finally, Clearbridge Investments LLC lifted its stake in Biohaven by 8.7% during the 4th quarter. Clearbridge Investments LLC now owns 521,099 shares of the company’s stock valued at $19,463,000 after acquiring an additional 41,850 shares during the period. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Biohaven Stock Down 9.8 %

Shares of NYSE BHVN opened at $18.54 on Monday. Biohaven Ltd. has a 52-week low of $17.93 and a 52-week high of $55.70. The company’s 50-day simple moving average is $33.40 and its 200-day simple moving average is $40.82. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of -1.98 and a beta of 1.33.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.29). Equities research analysts anticipate that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

Analyst Ratings Changes

BHVN has been the topic of a number of research reports. JPMorgan Chase & Co. cut their price objective on shares of Biohaven from $72.00 to $68.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biohaven in a research note on Tuesday, December 17th. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on Biohaven and gave the company a “buy” rating in a report on Thursday, March 20th. HC Wainwright reiterated a “buy” rating and set a $54.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. Finally, Morgan Stanley lowered their price objective on Biohaven from $69.00 to $63.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Fourteen research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $62.77.

Insider Transactions at Biohaven

In other Biohaven news, Director John W. Childs purchased 32,700 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were purchased at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the transaction, the director now owns 2,320,571 shares of the company’s stock, valued at $70,707,798.37. The trade was a 1.43 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 16.00% of the company’s stock.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.